Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of California, San Francisco
San Francisco, Estados UnidosPublications in collaboration with researchers from University of California, San Francisco (83)
2024
-
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682
-
Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)
Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828
-
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
JCI Insight, Vol. 8, Núm. 2
-
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome
Annals of surgery, Vol. 278, Núm. 5, pp. e1041-e1047
-
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome
Hepatology, Vol. 77, Núm. 5, pp. 1527-1539
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378
-
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8
-
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
Neoplasia (United States), Vol. 42
2022
-
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9